Can Daflon (micronized purified flavonoid fraction) be given together with tranexamic acid?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Daflon and Tranexamic Acid Be Given Together?

Yes, Daflon (micronized purified flavonoid fraction/MPFF) and tranexamic acid can be given together safely, as there are no documented drug interactions between these medications and they work through different mechanisms.

Mechanism and Safety Profile

These two medications operate through distinct pathways without overlapping contraindications:

  • Tranexamic acid is an antifibrinolytic agent that works by inhibiting plasminogen activation and preventing clot breakdown 1
  • MPFF (Daflon) is a venoactive drug that increases venous tone, improves lymphatic drainage, and normalizes capillary permeability 2

Evidence Supporting Combination Use

The 2021 hereditary hemorrhagic telangiectasia guidelines explicitly state that tranexamic acid "can be coadministered with systemic antiangiogenic therapy" 3. While this refers to bevacizumab specifically, it demonstrates that tranexamic acid can be safely combined with other vascular-acting medications.

Additionally, guidelines for hereditary angioedema recommend "a combination of tranexamic acid and attenuated androgens" for prophylaxis when first-line treatments are unavailable 4, further supporting the safety of tranexamic acid in combination regimens.

Important Safety Considerations

For Tranexamic Acid:

  • Contraindicated in patients with active intravascular clotting or subarachnoid hemorrhage 1
  • Avoid concomitant use with pro-thrombotic medications including Factor IX concentrates, anti-inhibitor coagulant concentrates, and hormonal contraceptives 1
  • Monitor for thromboembolic risk, especially in patients with atrial fibrillation or known thrombophilia 3
  • Dose adjustment required in renal impairment 1

For MPFF (Daflon):

  • Generally well-tolerated with minimal side effects 5, 6
  • No significant drug interactions documented in the literature
  • Can be used in various venous conditions including hemorrhoids and chronic venous disease 2, 5

Clinical Context for Combined Use

This combination may be particularly relevant in:

  1. Hemorrhoidal bleeding: MPFF is effective for hemorrhoid management 2, 5, while tranexamic acid can control acute bleeding episodes
  2. Chronic venous disease with bleeding: MPFF improves venous hemodynamics 6, 7, while tranexamic acid addresses bleeding complications
  3. Heavy menstrual bleeding: Both have been studied separately for this indication 8

Practical Recommendations

  • No dose adjustments are needed when combining these medications
  • Monitor for thrombotic events as you would with tranexamic acid alone, particularly in high-risk patients
  • Standard dosing: Tranexamic acid 500-1000 mg 2-4 times daily 3; MPFF 1000 mg once daily or 500 mg twice daily 9
  • Avoid adding other pro-thrombotic agents to this regimen

The absence of documented interactions in extensive clinical use, combined with their complementary mechanisms of action, supports the safety of this combination in appropriate clinical contexts.

References

Research

Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2018

Research

The Effects of Different Dosages on Micronized Purified Flavonoid Fraction's Treatment of Lower Limb Chronic Venous Disease: A Meta-Analysis.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2026

Related Questions

What is the recommended acute dosing regimen of Daflon (micronized purified flavonoid fraction) in adults with an acute flare of chronic venous disease or hemorrhoidal symptoms?
What is the CEAP classification system for chronic venous disease and how are its Clinical, Etiology, Anatomy, and Pathophysiology components defined?
What does the best evidence conclude about the comparison of mefenamic acid vs tranexamic acid for the treatment of heavy bleeding due to a copper Intrauterine Device (IUD)?
What are the symptoms and treatment options for a thrombosed hemorrhoid (thrombosed pile or external hemorrhoid)?
For adults with advanced (Goligher grade III–IV) hemorrhoidal disease awaiting surgery, does oral micronized purified flavonoid fraction (MPFF) provide better bleeding cessation, symptom relief, patient satisfaction, and safety compared with sublingual nano‑emulsion flavonoid therapy as a pre‑operative bridge?
What is the appropriate next step in management for a 26-year-old, 5 ft 11 in, 170 lb patient with persistent lateral shin numbness that began after an 18‑hour flight in late December and continues into early March?
In a 26‑year‑old, 5 ft 11 in, 170‑lb patient with sensory‑only peroneal nerve compression causing lateral shin numbness that began after an 18‑hour flight and has persisted for 2–3 months, when should recovery be expected if no specific treatment is provided?
What are the recommended starting doses and titration guidelines for clonidine for hypertension, ADHD, and opioid withdrawal?
How do you assess a patient for foot drop?
What is the significance of fibromuscular obliteration of the lamina propria in a rectal polyp in a 4‑year‑old female?
What are the causes of thrombocytopenia after endoscopic retrograde cholangiopancreatography (ERCP)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.